XOMA Royalty Corporation (XOMA)
(Delayed Data from NSDQ)
$29.25 USD
-0.25 (-0.85%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $29.27 +0.02 (0.07%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.25 USD
-0.25 (-0.85%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $29.27 +0.02 (0.07%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Zacks News
EU Unlikely to Approve Puma's Nerlynx in 2018, Stock Down
by Zacks Equity Research
Puma's (PBYI) shares decline after CHMP conveyed the company that the former will probably vote against the approval of breast cancer drug Nerlynx at the CHMP meeting scheduled in February.
Anthera's Sollpura Strong on Positive Futility in Phase III
by Zacks Equity Research
Anthera (ANTH) posts positive results from the second interim futility analysis of Sollpura for EPI. Top-line data from the study is expected in the first quarter of 2018.
Regeneron's Dupixent Receives MHLW Nod for Label Expansion
by Zacks Equity Research
Ministry of Health, Labor and Welfare (MHLW) in Japan has granted approval for the label expansion of Regeneron's (REGN) Dupixent.
Bristol-Myers (BMY) Reports Data from CheckMate-142 Study
by Zacks Equity Research
Bristol-Myers (BMY) announces new data from a cohort of the phase II CheckMate -142 study evaluating Opdivo (nivolumab) and Yervoy (ipilimumab).
Acorda Therapeutics (ACOR) Jumps: Stock Rises 8.8%
by Zacks Equity Research
Acorda Therapeutics (ACOR) was a big mover last session, as the company saw its shares nearly 9% on the day amid huge volumes.
Novo Nordisk's (NVO) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Regulatory approvals of some key pipeline candidates along with the strong performance of products like Victoza have contributed to a rally in Novo Nordisk's (NVO) shares.
3 Pharma and Biotech Stocks to Watch Out for in 2018
by Arpita Dutt
Here is a look at three pharma and biotech stocks including Alkermes (ALKS) that look well-positioned for 2018.
Aradigm's Bronchiectasis Candidate Has Negative FDA Vote
by Zacks Equity Research
The FDA panel votes against the approval of Aradigm's (ARDM) Linhaliq for treatment of non-cystic fibrosis bronchiectasis. A response from the regulatory agency is expected on Jan 26, 2018.
Perrigo (PRGO) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
We look at the factors that drive the share price of Perrigo to a 52-week high.
Vertex's Cystic Fibrosis Drug Ok'd for Pediatric Use in EU
by Zacks Equity Research
Vertex (VRTX) receives extension of the marketing application for Orkambi to include use in children with CF who have two copies of the F508del mutation from European Commission.
Why is Novo Nordisk Stock Up More Than 50% in Past Year?
by Zacks Equity Research
We take a look at the factors that led to the rise in Novo Nordisk's (NVO) share price in the past year.
Adamas (ADMS) Launches Dyskinesia Drug in the US, Stock Up
by Zacks Equity Research
Adamas (ADMS) shares climb on the commercial launch of Gocovri in the United States for treating dyskinesia in patients with Parkinson's disease. This is the first FDA approved drug for the ailment.
Acorda's Shares Down on Disappointing Ampyra View for 2018
by Zacks Equity Research
Acorda (ACOR) announces preliminary sales numbers of its key multiple sclerosis drug, Ampyra, for Q4. The company's net sales expectations are higher year over year.
Novo Nordisk Confirms Bid for Ablynx But Faces Rejection
by Zacks Equity Research
Novo Nordisk (NVO) confirmed its revised offer made on Dec 22, to acquire Ablynx NV for $3.1 billion.
Alnylam, Sanofi Announce Restructuring Deal for RNAi Products
by Zacks Equity Research
Alnylam (ALNY) and Sanofi entered into a strategic restructuring of their RNAi therapeutics rare genetic diseases alliance.
The Zacks Analyst Blog Highlights: XOMA, Exelixis, Emergent BioSolutions and Medicines
by Zacks Equity Research
The Zacks Analyst Blog Highlights: XOMA, Exelixis, Emergent BioSolutions and Medicines
4 Biotech Stocks to Watch in the New Year
by Zacks Equity Research
We take a look at four companies with a favorable Zacks Rank that performed well in 2017 and are likely to continue on the growth path in 2018 as well.
Emergent Starts Phase II Study on Anti-influenza Candidate
by Zacks Equity Research
Emergent (EBS) initiates a phase II dose-ranging trial to evaluate the safety, pharmacokinetics and clinical benefit of its investigational FLU-IGIV to treat influenza virus infection.
United Therapeutics (UTHR) Collaborates With Corsair Pharma
by Zacks Equity Research
United Therapeutics (UTHR) entered into an exclusive license agreement with Corsair Pharma.
Pfizer (PFE) Collaborates With Sangamo for Gene Therapy
by Zacks Equity Research
Pfizer entered into collaboration agreements with Sangamo Therapeutics and private biotech, Arvinas.
New Products Aid Boston Scientific, LOTUS Relaunch Lag Ails
by Zacks Equity Research
Boston Scientific (BSX) grows on product launches and international expansion. LOTUS relaunch delay hurts sales.
Thermo Fisher Buys Phenom-World, Aids Analytical Instruments
by Zacks Equity Research
On completion of Phenom-World purchase, Thermo Fisher (TMO) plans to integrate the business into its Analytical Instruments segment.
Inovio Amends Chinese Deal for Immunotherapy, Shares Up
by Zacks Equity Research
Inovio (INO) entered into an amended agreement with ApolloBio Corporation and grants ApolloBio the exclusive right to develop and commercialize VGX-3100 within Greater China.
Anika Therapeutics Receives FDA Nod for Bone Repair Therapy
by Zacks Equity Research
Anika Therapeutics' (ANIK) FDA approved HA-based injectable bone repair therapy provides a commercial edge to regenerative portfolio.
PetMed Rides on Solid Reorders & New Orders Amid Competition
by Zacks Equity Research
PetMed (PETS) strives to implement several strategies to revitalize the top line, focusing on advertising efficiency to boost new order sales and shifting sales to higher margin items.